

1 **Original Research Article**

2

3 **Association between antihypertensive combinations and postoperative mortality**
 4 **and functional decline: a nationwide survey of Japanese adults undergoing major**
 5 **surgeries**

6

7 Rena Suzukawa¹, Shintaro Mandai^{1*}, M.D., Ph.D., Yuta Nakano¹, M.D., Shunsuke
 8 Inaba¹, M.D., Hisazumi Matsuki¹, M.D., Yutaro Mori¹, M.D., Ph.D., Fumiaki Ando¹,
 9 M.D., Ph.D., Takayasu Mori¹, M.D., Ph.D., Koichiro Susa¹, M.D., Ph.D., Soichiro
 10 Iimori¹, M.D., Ph.D., Shotaro Naito¹, M.D., Ph.D., Eisei Sohara¹, M.D., Ph. D.,
 11 Tatemitsu Rai², M.D., Ph. D., Kiyohide Fushimi³, M.D., Ph.D., Shinichi Uchida¹, M.D.,
 12 Ph.D.

13

14 ¹Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo
 15 Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo 113-8519, Japan

16 ²Department of Nephrology and Hypertension, Dokkyo Medical University, 880
 17 Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan

18 ³Department of Health Policy and Informatics, Graduate School of Medical and Dental
 19 Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo
 20 113-8519, Japan

21

22 Suzukawa R and Mandai S contributed equally.

23

24 Short title: Antihypertensive class and postoperative outcomes

25

26 *Corresponding Author: Shintaro Mandai (ORCID iD: 0000-0001-6709-306X)

27 Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo

28 Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo 113-8519, Japan

29 Tel: +81-3-5803-5214; Fax: +81-3-5803-5215; E-mail: smandai.kid@tmd.ac.jp

30

31 Total word count: 3,543

32 Abstract

33 **Background:** Considering the limited information available regarding the impact of
 34 antihypertensive classes on mortality and physical function during hospitalization, we
 35 aimed to clarify the impact of six antihypertensive classes, namely thiazide/thiazide-like
 36 diuretics (TH), calcium receptor blockers (CCBs), renin–angiotensin–aldosterone
 37 system inhibitors (RASIs), mineral corticoid receptor antagonists, α -blockers, and
 38 β -blockers, on outcomes in adult patients undergoing major surgeries.

39 **Methods:** This study was a subanalysis of a nationwide observational cohort study
 40 involving Japanese adults undergoing major surgeries from 2018 to 2019 using an
 41 administrative claims database. We recruited 473,327 antihypertensive medication users
 42 and 376,583 nonusers aged ≥ 50 years who underwent six different types of surgeries,
 43 including coronary artery bypass grafting (CABG), thoracic lobectomy, orthopedic
 44 surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological
 45 surgery. The risk for overall death or functional decline, defined as a ≥ 5 -point decrease
 46 in the Barthel Index score during hospitalization, was determined using multivariable
 47 logistic regression models.

48 **Results:** All-cause inhospital deaths occurred in 5,777 (1.2%) users and 2,657 (0.7%)
 49 nonusers. Functional decline was observed in 42,930 (9.2%) users and 22,550 (6.0%)

nonusers. Among single class users, RASi use had a multivariable odds ratio (OR) of 0.77 (95% confidence interval (CI) 0.63–0.93 vs. TH) for the composite of mortality and functional decline. β -Blocker use was associated with an increased risk for functional decline (OR 1.27, 95% CI 1.01–1.60 vs. TH). Among the recipients of the two medication classes, TH/RASi usage was associated with the lowest risk for composite outcome (OR 0.68, 95% CI 0.60–0.77 vs. TH/CCB). Among the recipients of the three or more medication classes, TH/CCB/RASi or TH/CCB/RASi/other displayed the lowest odds for composite outcome (OR 0.72, 95% CI 0.49–0.82 vs. TH/CCB/other; OR 0.63, 95% CI 0.49–0.82 vs. TH/CCB/others). A stratified analysis revealed that RASi users had a lower OR for the composite outcome after major surgery categories except CABG than non-RASi users.

Conclusions: RASis were associated with decreased risk of postoperative mortality and functional decline regardless of the number of antihypertensive classes or surgery type. Managing hypertension through multidrug combinations, including RASis, may mitigate mortality and loss of physical function during the perioperative period.

Clinical Perspective

What is new?

68 ● This nationwide observational cohort study of Japanese adults undergoing major
69 surgeries from 2018 to 2019 using an administrative claims database showed
70 that all-cause inhospital deaths occurred in 5,777 (1.2%) antihypertensive users
71 and 2,657 (0.7%) nonusers, whereas functional decline was observed in 42,930
72 (9.2%) antihypertensive users and 22,550 (6.0%) nonusers.

73 ● We found that an increase in the number of antihypertensive classes used,
74 indicative of patients with treatment-resistant hypertension, was associated with
75 a higher risk of mortality and loss of physical function, partly attributed to loop
76 diuretic use for congestion.

77 What are the clinical implications?

78 ● This study determined combinations of antihypertensive drugs that potentially
79 improve the outcomes of antihypertensive users undergoing major surgeries,
80 with the favorable regimens including RASis independent of the number of
81 antihypertensive classes used.

82 ● After undergoing all major surgery categories except CABG, patients on RASis
83 were at a lower risk of death and functional decline than those who were treated
84 with other antihypertensive classes.

85

86 **Keywords:** hypertension, antihypertensive class, surgery, physical function,

87 renin–angiotensin–aldosterone system inhibitor

88

89 **Nonstandard Abbreviations and Acronyms**

90 ACEi angiotensin-converting enzyme inhibitor

91 AKI acute kidney injury

92 ADL activities of daily living

93 AHT acute hypertension

94 ARB angiotensin II receptor blocker

95 BMI body mass index

96 CABG coronary artery bypass grafting

97 CCB calcium channel blocker

98 CI confidence intervals

99 CKD chronic kidney disease

100 CVD cardiovascular disease

101 DM diabetes mellitus

102 DPC diagnosis procedure combination

103 ESKD end-stage kidney disease

104 ICD-10 International Classification of Disease and Related Health Problems,

105 10th Revision

106 IQR interquartile range

107 MRA mineral corticoid receptor antagonist

108 OR odds ratio

109 RAS renin–angiotensin system
 110 RASi renin–angiotensin–aldosterone system inhibitor
 111 ROS reactive oxygen species
 112 TH thiazide/thiazide-like diuretics

113

114 **Introduction**

115 The proportion of patients with hypertension continues to increase globally. The
 116 number of adult patients with hypertension doubled from 1990 to 2019, affecting nearly
 117 1,300 million people worldwide [1]. Although recent advances in antihypertensive
 118 medications and their widespread availability have improved hypertension control in
 119 this population, the prevalence of treatment-resistant hypertension requiring a
 120 combination of multiple antihypertensive classes has continued to increase [2-5]. When
 121 caring for patients with hypertension, the prevention of chronic systemic organ
 122 dysfunction, hospitalization, acute kidney injuries (AKI), and death caused by acute
 123 hypertension (AHT) is of considerable importance [6]. We previously reported an
 124 increase in absolute death and urgent dialysis due to AHT from 2010 to 2019 among
 125 hospitalized Japanese patients [6]. Given the lack of comprehensive investigations on
 126 the effective combination of antihypertensive classes and the mostly empiric evidence
 127 available [4], understanding the effects of various antihypertensive medications and

128 their management approaches for both in- and outpatients has been of notable interest

129 among physicians.

130 The decline in activities of daily living (ADLs) and frailty related to

131 hospitalization have also been an enormous health concern for inpatients, given the

132 exponential increase in the aging population globally. Previous studies have established

133 that the use of angiotensin-converting enzyme inhibitors (ACEis) has long-term effects

134 on muscle strength [7,8]. The use of angiotensin II receptor blockers (ARBs) promotes

135 enhanced exercise capacity among patients with heart failure [9]. In contrast, our studies

136 showed that patients taking loop diuretics were at an increased risk of developing

137 sarcopenia [10,11], with subsequent studies reporting the same correlation among

138 patients with heart failure and hepatopathy [12-14]. However, no study has focused on

139 the effects of antihypertensive class or loop diuretics during hospitalization under acute

140 care settings, i.e., in patients with severe diseases (e.g., cardiovascular diseases [CVDs],

141 infectious diseases, or major surgeries). We evaluated the impact of continued empirical

142 antihypertensive drug administration during hospitalization on postoperative outcomes,

143 including mortality and physical function, after major surgeries.

144 The current study aimed to determine the most effective monotherapy or

145 combination therapy among six antihypertensive classes (i.e., thiazide/thiazide-like

146 diuretics [TH], calcium receptor blockers [CCBs], renin–angiotensin–aldosterone
147 system inhibitors [RASIs], mineral corticoid receptor antagonists [MRAs], α -blockers,
148 and β -blockers) and loop diuretics, which helps lower the risk for postoperative
149 mortality and functional decline among patients aged 50 and older who underwent
150 major surgeries during hospitalization. We also aimed to investigate whether the type of
151 major surgery (i.e., coronary artery bypass grafting [CABG], thoracic lobectomy,
152 orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and
153 urological surgery) altered the association between antihypertensive class and
154 postoperative outcomes.

155

156 **Methods**

157 *Study design and participants*

158 This study was a *posthoc* subanalysis of a national survey on postoperative
159 outcomes among Japanese adults undergoing major surgeries [15]. We used an
160 administrative claims database, the Diagnosis Procedure Combination (DPC) inpatient
161 database, to obtain data from 2018 to 2019 [6,15,16]. This dataset comprises
162 information obtained from over 1000 hospitals, including all 82 teaching hospitals, and
163 covers half or more of inpatient cases throughout Japan. The available information

164 included diagnosis and comorbidities upon hospital admission coded according to the
165 International Classification of Disease and Related Health Problems, 10th Revision [14].
166 The datasets also included information on patients' age, sex, body mass index (BMI),
167 the Charlson comorbidity index [17], which was updated for risk adjustment [18],
168 ADLs upon admission and discharge, and discharge status.

169 A total of 15,422,773 eligible cases were identified. The criteria for study
170 inclusion included age ≥ 50 years, hospitalization ≥ 24 h, and patients undergoing any of
171 the defined major surgeries. Major surgeries were previously defined as invasive
172 operative procedures, including CABG, thoracic lobectomy, orthopedic surgery (hip or
173 knee arthroplasty, laminectomy or spinal fusion, and surgery for hip fracture or
174 dislocation), hepatopancreatobiliary surgery (hepatic lobectomy, cholecystectomy, and
175 pancreatectomy), gastrointestinal resection (esophagectomy, gastrectomy, and
176 colectomy), and urological surgery (cystectomy and nephrectomy) [15,19]. The
177 exclusion criteria were as follows: second or later admissions; patients with incomplete
178 information on BMI, the Barthel Index, and admission type (emergency admission or
179 not); those who underwent multiple surgery types; and dependence on maintenance
180 dialysis therapy. Dependence on hemodialysis or peritoneal dialysis was determined
181 from the coding of patient care procedures (chronic maintenance hemodialysis with <4

182 h per session, ≥ 4 h but < 5 h per session, ≥ 5 h per session or chronic maintenance

183 hemodiafiltration or continuous peritoneal dialysis) [17].

184 Our study protocol was approved by the ethics committee of Tokyo Medical and

185 Dental University. The need for informed consent was waived because the data were

186 anonymized. The study was conducted in accordance with the ethical principles of the

187 Declaration of Helsinki. The data used for the study analyses are available from the

188 corresponding author S.M. upon reasonable request.

189

190 *Patient characteristics*

191 We calculated the Barthel Index scores upon admission and discharge based on

192 10 functional abilities, including feeding, bathing, grooming, dressing, bowel control,

193 bladder control, toileting, chair transfer, ambulation, and climbing stairs [20]. Barthel

194 Index scores ranged from 0 to 100 at 5-point increments, with 0 indicating complete

195 bed-ridden status and 100 indicating full independence of physical functions. Other

196 patient information on admission included age, sex, BMI, dependence on urgent or

197 maintenance kidney replacement therapy, updated Charlson comorbidity index,

198 excluding renal disease [17,18], comorbidity, surgery type, admission type (emergency

199 or elective admission), and fiscal year. We used the following age strata for the

200 analyses: 50–59, 60–69, 70–79, and ≥ 80 years [21]. On the basis of previous studies,

201 antihypertensive medications were classified into six groups, including TH, CCBs,

202 RASIs, MRAs, α -blockers, and β -blockers [22, 23]. Thiazide-like diuretics without a

203 benzothiadiazide structure, such as indapamide and metolazone, were also categorized
204 under TH. Only dihydropyridines were included as CCBs in this study. RASIs included
205 ACEIs and ARBs. Notably, α/β -blockers were included under β -blockers. Loop
206 diuretics were recognized when used both orally and intravenously.

207

208 *Outcomes*

209 The primary outcome was the composite of overall inhospital death and decline
210 in physical function, which was defined as a 5-point lower Barthel Index score [24] at
211 discharge than at admission. Patients were followed up until discharge, transfer, or
212 inhospital death.

213

214 *Data analyses*

215 Data were presented as number (percentage) or median (interquartile range
216 [IQR]). Logistic regression models were used to assess the association between
217 antihypertensive medication and loop diuretics and the risk for mortality or functional
218 decline, adjusting for potential confounding measurements, including age, sex, type of
219 major surgeries, BMI, Barthel Index score upon admission, diabetes mellitus (DM),
220 CVD, chronic kidney disease (CKD), emergency admission, and year of admission. We
221 conducted subgroup analyses using logistic regression models to determine the

association between antihypertensive class and outcomes according to major surgery type. All statistical analyses were performed using Stata version 15.0 (Stata Corp., College Station, TX, United States), with $P < 0.05$ indicating statistical significance.

Results

Patient characteristics

We identified 15,422,773 patients from a Japanese national inpatient database between 2018 and 2019 (Fig. S1). Subjects aged 50 years and older who underwent major operations during hospitalization lasting for at least 24 h were included ($n = 1,283,540$). Subsequently, those on their second or later admissions; those without complete information on BMI, Barthel Index score, or emergency admission; and those who underwent multiple surgeries or received maintenance dialysis were excluded. In total, 849,910 subjects were included in the analysis.

Table 1 summarizes the demographics and characteristics of the study cohort.

Among the 849,910 patients, 473,327 (56%) were taking at least one class of antihypertensive medication. Antihypertensive users and nonusers had a median age (IQR) of 76 (69–82) years and 70 (63–78) years, female percentage of 49% and 50%, and median BMI of 23.4 (20.9–26.0) kg/m^2 and 22.5 (20.2–24.9) kg/m^2 , respectively. A

240 larger proportion of antihypertensive users than nonusers had a low Barthel Index score.
241 The prevalence of comorbidities, including CVD, DM, and CKD, was higher among
242 antihypertensive users than among nonusers. Patients were also stratified according to
243 the type of major surgery that they underwent during hospitalization. Among the six
244 types of major surgeries (CABG, thoracic lobectomy, orthopedic surgery,
245 hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery),
246 orthopedic surgery was the most common in both groups (45% and 37%, respectively),
247 followed by gastrointestinal resection and esophagectomy (20% and 25%, respectively).

248

249 *Effects of the number of antihypertensive classes on postoperative outcomes*

250 After a median follow-up of 17 (IQR, 10–27) days, all-cause in-hospital deaths
251 were observed in 5,777 patients (1.2%) out of 473,327 antihypertensive users and 2,657
252 patients (0.7%) out of 376,583 nonusers. Functional decline was observed in 22,550
253 (6.0%) nonusers and 42,930 (9.2%) users. Figure 1 displays the prevalence of all-cause
254 in-hospital death and functional decline after survival according to age category. The
255 proportions of mortality and functional decline were higher among patients on more
256 antihypertensive classes than among those on no or fewer antihypertensive classes. This

257 indicates a significant association between resistance and antihypertensive treatment
 258 and the crude mortality rate and decline in ADLs (Figure 1)

259 Thereafter, multivariable logistic regression models were created to determine
 260 the aggregate risk for all-cause in-hospital death and functional decline after survival. In
 261 the age- and sex-adjusted model, the odds ratios (ORs) for a composite outcome of
 262 mortality and functional decline were 1.20 (95% confidence interval [CI], 1.18–1.23),
 263 1.23 (95% CI, 1.20–1.25), 1.42 (95% CI, 1.38–1.47), and 1.57 (95% CI, 1.49–1.65) for
 264 users receiving one, two, three, and four or more classes of antihypertensives when
 265 compared with nonusers (Table 2). Similarly, in Models 2 and 3, which adjusted for
 266 DM, CVD, CKD, emergency admission, and admission year, the use of more
 267 antihypertensive classes was associated with a higher risk for the composite outcome.

268 After additionally adjusting for the use of loop diuretics (Model 4), the odds for the
 269 composite outcome were comparable between users receiving one, two, three, and four
 270 or more classes of antihypertensives. These findings indicate that congestion requiring
 271 the use of loop diuretics is a major confounding factor for the association between
 272 resistant hypertension and unfavorable postoperative outcomes.

273

274 *Combinations of antihypertensive classes and postoperative outcomes*

275 We then investigated whether differences in postoperative outcomes following
276 major surgeries were present according to different combinations of antihypertensive
277 classes among the patients.

278 Among those who used only one of the six antihypertensive classes and loop
279 diuretics, RASi showed the lowest OR for composite outcome, mortality, and
280 functional decline (Table 3). With TH as the reference, RASi showed 0.77-, 0.58-, and
281 0.79-times lower odds for the composite outcome (95% CI, 0.63–0.93; $P = 0.008$),
282 mortality (95% CI, 0.34–0.99; $P = 0.045$), and functional decline (95% CI, 0.64–0.96; P
283 $= 0.020$), respectively, whereas β -blockers showed a 1.27-times higher odds for
284 functional decline (95% CI, 1.01–1.60; $P = 0.040$; Table 3). Among those who used two
285 antihypertensive classes, the combination of THs and RASi showed the lowest OR for
286 each outcome. Compared with TH/CCB, TH and RASi had an OR of 0.68 for the
287 composite outcome (95% CI, 0.60–0.77; $P < 0.001$; Table 3). Among those who used
288 three or more classes of antihypertensive, combinations including CCB and RASi
289 showed the lowest OR for each outcome. In comparison, using the combination of TH,
290 CCB, and other as the reference, the combination of TH, CCB, and RASi showed odds
291 of 0.72-, 0.43-, and 0.79-times lower for the composite outcome (95% CI, 0.49–0.82; P
292 < 0.001), mortality (95% CI, 0.31–0.60; $P < 0.001$), and functional decline (95% CI,

0.70–0.89; $P < 0.001$; Table 3), respectively. The use of RASis was significantly associated with a lower OR for postoperative outcomes regardless of the number of antihypertensive classes used for treatment. A comparison of those who did and did not use loop diuretics showed that loop diuretic use consistently resulted in significantly higher ORs for the composite outcome, mortality, and functional decline regardless of the number of other antihypertensive medications used (Table S1).

Impact of each antihypertensive class on postoperative outcomes according to the type of major surgery

We performed a stratified analysis on the impact of each antihypertensive class on postoperative outcomes according to six types of major surgeries (CABG, thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery). Notably, RASis were associated with lower ORs for the composite outcome of death and functional decline, all-cause in-hospital death, and survival with functional decline among those who underwent five types of major surgeries except CABG (Figure 2). Only β -blocker use was associated with better outcomes among patients who underwent CABG (OR, 0.77; 95% CI, 0.67–0.89).

311 Discussion

312 The current large-scale epidemiologic cohort study using the Japanese
313 administrative claims database clarified the effects of antihypertensive drugs on
314 postoperative mortality and functional decline in patients aged 50 and older. First, we
315 found that an increase in the number of antihypertensive classes, which indicated
316 treatment-resistant hypertension, was associated with a higher risk of mortality and loss
317 of physical function, partly attributed to loop diuretic use needed for congestion. Second,
318 we determined combinations of antihypertensives that potentially improve the outcomes
319 of antihypertensive users undergoing major surgeries. The favorable regimens included
320 RASis independent of the number of antihypertensive classes used. Third, among
321 patients who underwent any type of major surgery, excluding CABG, those on RASis
322 were at a lower risk of death and functional decline than those not treated with other
323 antihypertensive classes.

324 The primary finding of the current study was that patients who received RAS
325 inhibition had a lower risk for the composite outcome of all-cause inhospital death and
326 functional decline after surviving major surgeries than those without RAS inhibition,
327 independent of the number of antihypertensive classes used. RAS inhibition in patients
328 treated with ACEi and ARB is known to help decrease skeletal muscle loss [7-9]. A

329 plausible explanation for its underlying pathological mechanism is the suppression of
330 angiotensin II-induced impairment in protein synthesis, acceleration of protein
331 breakdown, and loss of appetite. Angiotensin II increases the levels of cytokines and
332 systemic hormones, including reactive oxygen species, insulin-like growth factor 1,
333 tumor necrosis factor alpha, interleukin-6, and transforming growth factor beta [7-9,
334 24-28]. The current study showed that among patients who used a single class of
335 antihypertensive, those who used RASi had lower odds for the composite outcome of
336 mortality and functional decline than those who used TH. Among those who received
337 two classes of antihypertensives, those who received a combination of TH/RASi had an
338 OR of 0.68 for the composite outcome compared with those on TH/CCB. The favorable
339 effects of RASis on mortality and functional decline were also observed among those
340 who used three or more antihypertensive classes. Our data clearly showed that RAS
341 interfered with functional decline, although pathological analysis at the molecular level
342 was not conducted.

343 Our findings showed that β -blocker users had a 1.27-fold higher OR for
344 functional decline than TH users, which is consistent with previous findings on the
345 association between β -blocker and functional decline in patients with end-stage kidney
346 disease (ESKD) [29], CVD, and heart failure [30, 31]. In our previous study on a cohort

347 with ESKD, β -blocker users had 2.5-fold higher odds of annual skeletal muscle mass
348 loss, whereas the use of RASi in combination with other medications minimized the
349 adverse effects [29]. Notably, only the use of β -blockers was markedly associated with a
350 lower risk for postoperative composite outcome in patients who underwent CABG.
351 Therefore, the current study reaffirms the positive effects of RASi on skeletal muscle
352 mass in acute care settings among patients undergoing major surgeries [29].
353 Nonetheless, further investigations are needed to uncover the mechanism underlying the
354 association between RAS inhibition and favorable outcomes after major surgeries,
355 excluding CABG.

356 Our findings showed that outcomes following major surgeries could be further
357 improved by combining empirically antihypertensive drugs prescribed. Frailty, often
358 defined as unintentional weight loss, has been shown to be associated with mortality
359 among inhospital patients [32], as well as postdischarge patients or outpatients [33-35].
360 Newly acquired functional decline among older persons owing to hospital admissions is
361 especially serious given the already high prevalence of frailty among
362 community-dwelling people in the aging Japanese society [36] and its association with
363 higher mortality and economic burden. Our findings showed that 9.2% of
364 antihypertensive drug users and 6.0% of nonusers experienced a decrease in their

365 Barthel Index score during hospitalization, a figure even higher than the 7.4% overall
 366 pooled prevalence of frailty among Japanese community-dwelling people aged 65 and
 367 older reported in a previous review [36]. This suggests that the probability of functional
 368 decline is primarily higher among inpatients and that patients with hypertension are at
 369 substantially higher risk. Thus, combinations of antihypertensive drugs, including
 370 RASIs, may improve the clinical outcomes of patients with hypertension by minimizing
 371 functional decline through internal treatment during the acute phase of hospitalization.

372 A substantial proportion of patients worldwide remain resistant to hypertension
 373 treatment and are usually treated with more antihypertensive medication classes.
 374 However, the optimal combinations of antihypertensives are yet to be fully understood.
 375 As expected, our findings showed that the number of antihypertensive classes was
 376 positively correlated with the risk of mortality and functional decline. Indeed, we found
 377 that patients on multiple antihypertensive medications were at a greater risk for the
 378 composite outcome, even after adjusting for potential confounders. Notably, after
 379 adjusting for the use of loop diuretics, the odds for the risk of the composite outcome
 380 were similar regardless of the number of antihypertensive classes used, suggesting that
 381 loop diuretic usage was a powerful confounding factor associated with mortality and
 382 functional decline. Loop diuretics are indispensable in addressing fluid retention among

383 patients with renal and heart failure. One possible side effect of loop diuretics is
384 sarcopenia, as discussed in previous studies [10-14]. Na⁺-K⁺-2Cl⁻ cotransporter 1,
385 which is highly expressed in mammalian skeletal muscle and inhibited by furosemide,
386 might help prevent muscle loss based on its background pharmacological mechanism
387 [10]; however, the pathological pathway has yet to be not fully elucidated.

388 One strength of the current study is that we used well-validated Japanese
389 administrative data representing a sample of the general population. The validity of the
390 diagnoses and procedural records in the Japanese DPC database was corroborated in a
391 previous study [37]. However, several limitations need to be acknowledged. First, this
392 study was exclusively conducted on a single race or ethnicity. Evidence suggests that
393 Asian populations have a higher prevalence of uncontrolled hypertension [38]. Hence,
394 our findings may not be generalizable to other ethnicities. Second, the use of more than
395 one antihypertensive drug within the same antihypertensive class was under-represented
396 in this study. Third, given the nature of the datasets used herein, we were unable to
397 determine changes in blood pressure and antihypertensive drug use during
398 hospitalization potentially caused by poor control, complications, or side effects. The
399 number of antihypertensive classes may have been overestimated. Finally, the database
400 lacked biochemical data and longitudinal outcomes after discharge. Our study focused

401 only on the effects of antihypertensive medication on postoperative mortality and
 402 functional decline during the acute phase of hospitalization following major surgeries.
 403 A previous multicenter retrospective cohort study showed that the postoperative
 404 initiation of RASis even at discharge was associated with reduced long-term mortality
 405 rate in patients undergoing cardiac surgery [39]. Randomized controlled trials are
 406 needed to determine whether perioperative RASi initiation could improve outcomes
 407 following cardiac and non-cardiac surgeries.

408 In conclusion, the current study highlights the effects of antihypertensive classes
 409 and their combinations on the risk of postoperative mortality and functional decline.
 410 Our findings showed that RASis usage had a positive prognostic impact on
 411 postoperative in-hospital death and functional decline regardless of the number of
 412 antihypertensive medication classes used. Thus, RASi use may mitigate negative
 413 postoperative outcomes after major noncardiac surgeries.

414

415 **Acknowledgments**

416 We would like to thank all study participants.

417

418 **Sources of Funding**

419 This study was supported by the Health and Labour Sciences Research Grant (Grant No.

420 Seisaku-Sitei-22AA2003 to KF) of the Japan Ministry of Health, Labour and Welfare.

421

422 **Disclosures**

423 **Conflict of interest**

424 None.

425

426 **References**

427 1. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA,

428 Gregg EW, Bennett JE, Solomon B, Singleton RK, et al. Worldwide trends in

429 hypertension prevalence and progress in treatment and control from 1990 to 2019: a

430 pooled analysis of 1201 population-representative studies with 104 million participants.

431 *Lancet*. 2021;398:957–980.

432 2. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL,

433 Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, et al. Resistant

434 hypertension: detection, evaluation, and management: A scientific statement from the

435 American Heart Association. *Hypertension*. 2018;72:e53–e90.

3. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. *Hypertension*. 2011;57:1076–1080.
4. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood pressure research. *Hypertension*. 2008;51:1403–1419.
5. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nat Rev Nephrol*. 2020;16:223–237.
6. Matsuki H, Genma T, Mandai S, Fujiki T, Mori Y, Ando F, Mori T, Susa K, Iimori S, Naito S, et al. National trends in mortality and urgent dialysis after acute hypertension in Japan from 2010 through 2019. *Hypertension*. 2023;80:2591–2600.
7. Dr Onder G, Penninx BWJH, Balkrishnan R, Fried LP, Chaves PH, Williamson J, Carter C, Di Bari M, Guralnik JM, Pahor M. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. *Lancet*. 2002;359:926–930.
8. Di Bari M, van de Poll-Franse LV, Onder G, Kritchevsky SB, Newman A, Harris TB, Williamson JD, Marchionni N, Pahor M, Health, Aging and Body

- 454 Composition Study. Antihypertensive medications and differences in muscle mass in
455 older persons: the health, aging and body composition study. *J Am Geriatr Soc*.
456 2004;52:961–966.
- 457 9. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G,
458 Olivari MT, Thomas S, Le Jemtel TH. Addition of angiotensin II receptor blockade to
459 maximal angiotensin-converting enzyme inhibition improves exercise capacity in
460 patients with severe congestive heart failure. *Circulation*. 1999;99:990–992.
- 461 10. Mandai S, Furukawa S, Kodaka M, Hata Y, Mori T, Nomura N, Ando F, Mori Y,
462 Takahashi D, Yoshizaki Y, et al. Loop diuretics affect skeletal myoblast differentiation
463 and exercise-induced muscle hypertrophy. *Sci Rep*. 2017;7:46369.
- 464 11. Ishikawa S, Naito S, Iimori S, Takahashi D, Zeniya M, Sato H, Nomura N,
465 Sohara E, Okado T, Uchida S, et al. Loop diuretics are associated with greater risk of
466 sarcopenia in patients with nondialysis-dependent chronic kidney disease. *PLOS ONE*.
467 2018;13:e0192990.
- 468 12. Hanai T, Shiraki M, Miwa T, Watanabe S, Imai K, Suetsugu A, Takai K,
469 Moriwaki H, Shimizu M. Effect of loop diuretics on skeletal muscle depletion in
470 patients with liver cirrhosis. *Hepatol Res*. 2019;49:82–95.

- 471 13. Felker GM, O'Connor CM, Braunwald E, Heart Failure Clinical Research
472 Network Investigators. Loop diuretics in acute decompensated heart failure: necessary?
473 Evil? A necessary evil? *Circ Heart Fail.* 2009;2:56–62.
- 474 14. Nakano I, Tsuda M, Kinugawa S, Fukushima A, Kakutani N, Takada S, Yokota
475 T. Loop diuretic use is associated with skeletal muscle wasting in patients with heart
476 failure. *J Cardiol.* 2020;76:109–114.
- 477 15. Nakano Y, Mandai S, Genma T, Akagi Y, Fujiki T, Ando F, Susa K, Mori T,
478 Iimori S, Naito S, et al. Nationwide mortality associated with perioperative acute
479 dialysis requirement in major surgeries. *Int J Surg.* 2022;104:106816.
- 480 16. Isogai T, Yasunaga H, Matsui H, Tanaka H, Horiguchi H, Fushimi K.
481 Effectiveness of inferior vena cava filters on mortality as an adjuvant to antithrombotic
482 therapy. *Am J Med.* 2015;128:312.e23–312.e31.
- 483 17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
484 prognostic comorbidity in longitudinal studies: development and validation. *J Chron*
485 *Dis.* 1987;40:373–383.
- 486 18. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM,
487 Sundararajan V. Updating and validating the Charlson comorbidity index and score for

488 risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J*
489 *Epidemiol.* 2011;173:676–682.

490 19. Bykov K, Bateman BT, Franklin JM, Vine SM, Patorno E. Association of
491 gabapentinoids with the risk of opioid-related adverse events in surgical patients in the
492 United States. *JAMA Netw Open.* 2020;3:e2031647.

493 20. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index, *Md Stat.*
494 *Med J.* 1965;14:61–65.

495 21. Kessler M, Frimat L, Panescu V, Briançon S. Impact of nephrology referral on
496 early and midterm outcomes in ESRD: EPIdemiologie de l’insuffisance RENale
497 chronique terminale en Lorraine (EPIREL): results of a 2-year, prospective,
498 community-based study. *Am J Kidney Dis.* 2003;42:474–485.

499 22. Rethy LB, Feinstein MJ, Achenbach CJ, Townsend RR, Bress AP, Shah SJ,
500 Cohen JB. Antihypertensive class and cardiovascular outcomes in patients with HIV
501 and hypertension. *Hypertension.* 2021;77:2023–2033.

502 23. Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M,
503 Chalmers J, Teo KK, Pepine CJ, Davis BR, et al. Antihypertensive treatment and risk of
504 cancer: an individual participant data meta-analysis. *Lancet Oncol.* 2021;22:558–570.

- 505 24. Tasheva P, Vollenweider P, Kraege V, Roulet G, Lamy O, Marques-Vidal P,
506 Méan M. Association between physical activity levels in the hospital setting and
507 hospital-acquired functional decline in elderly patients. *JAMA Netw Open*.
508 2020;3:e1920185.
- 509 25. Zhao W, Swanson SA, Ye J, Li X, Shelton JM, Zhang W, Thomas GD. Reactive
510 oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin
511 II-dependent hypertension. *Hypertension*. 2006;48:637–643.
- 512 26. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and
513 decreases circulating insulin-like growth factor I in rats through a pressor-independent
514 mechanism. *J Clin Invest*. 1996;97:2509–2516.
- 515 27. Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, Battista
516 Ambrosio G, Vescovo G. Beneficial effects on skeletal muscle of the angiotensin II type
517 1 receptor blocker irbesartan in experimental heart failure. *Circulation*.
518 2001;103:2195–2200.
- 519 28. Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL,
520 Walston JD, Ward CW, Cohn RD. Losartan restores skeletal muscle remodeling and
521 protects against disuse atrophy in sarcopenia. *Sci Transl Med*. 2011;3:82ra37.

- 522 29. Hashimoto H, Mandai S, Shikuma S, Kimura M, Toma H, Sakaguchi Y,
523 Shiraishi S, Toshima N, Hoshino M, Kimura M, et al. The effect of antihypertensive
524 therapy on skeletal muscle mass and bone mineral density in patients with end-stage
525 kidney disease. *J Ren Nutr.* 2023. <https://doi.org/10.1053/j.jrn.2023.10.008>.
- 526 30. Steinman MA, Zullo AR, Lee Y, Daiello LA, Boscardin WJ, Dore DD, Gan S,
527 Fung K, Lee SJ, Komaiko KD, et al. Association of β -blockers with functional
528 outcomes, death, and rehospitalization in older nursing home residents after acute
529 myocardial infarction. *JAMA Intern Med.* 2017;177:254–262.
- 530 31. Palau P, Seller J, Domínguez E, Sastre C, Ramón JM, de La Espriella R, Santas
531 E, Miñana G, Bodí V, Sanchis J, et al. Effect of β -blocker withdrawal on functional
532 capacity in heart failure and preserved ejection fraction. *J Am Coll Cardiol.*
533 2021;78:2042–2056.
- 534 32. Mandai S, Koide T, Fujiki T, Mori Y, Ando F, Susa K, Mori T, Iimori S, Naito
535 S, Sohara E, et al. Association of Admission functional status and body mass index with
536 mortality in patients receiving chronic dialysis: A nationwide observational cohort study.
537 *JMA J.* 2023;6:404–413.

- 538 33. Pandey, A, Kitzman, D, Reeves, G. Frailty is intertwined with heart failure:
539 mechanisms, prevalence, prognosis, assessment, and management. *J Am Coll Cardiol*
540 HF. 2019;7:1001–1011.
- 541 34. Kulmala J, Nykänen I, Hartikainen S. Frailty as a predictor of all-cause mortality
542 in older men and women. *Geriatr Gerontol Int*. 2014;14:899–905.
- 543 35. Brummel NE, Bell SP, Girard TD, Pandharipande PP, Jackson JC, Morandi A,
544 Thompson JL, Chandrasekhar R, Bernard GR, Dittus RS, et al. Frailty and Subsequent
545 Disability and Mortality among Patients with Critical Illness. *Am J Respir Crit Care*
546 *Med*. 2017;196:64–72.
- 547 36. Kojima G, Iliffe S, Taniguchi Y, Shimada H, Rakugi H, Walters K. Prevalence
548 of frailty in Japan: a systematic review and meta-analysis. *J Epidemiol*.
549 2017;27:347–353.
- 550 37. Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H.
551 Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. *J*
552 *Epidemiol*. 2017;27:476–482.
- 553 38. Park JB, Kario K, Wang JG. Systolic hypertension: an increasing clinical
554 challenge in Asia. *Hypertens Res*. 2015;38:227–236.

555 39. Ding Q, Zhang Z, Liu H, Nie H, Berguson M, Goldhammer JE, Young N, Boyd
556 D, Morris R, Sun J. Perioperative use of renin-angiotensin system inhibitors and
557 outcomes in patients undergoing cardiac surgery. *Nat Commun.* 2019;10:4202.
558
559

560 Tables

561 **Table 1. Characteristics of patients aged 50 years and older undergoing major**
562 **surgeries**

	Treatment with antihypertensive medications (n = 473,327)	No treatment (n = 376,583)
Age (year)	76 (69–82)	70 (63–78)
Female	230417 (49)	187556 (50)
BMI (kg/m ²)	23.4 (20.9–26.0)	22.5 (20.2–24.9)
Barthel Index score		
0–25	82671 (17)	45681 (12)
30–55	23467 (5)	14150 (4)
60–85	24738 (5)	14592 (4)
90–100	342451 (72)	302160 (80)
Cardiovascular disease	82490 (17)	22696 (6)
Diabetes mellitus	123050 (26)	55841 (15)
Chronic kidney disease	25046 (5)	6468 (2)
Emergency admission	134369 (28)	91961 (24)
Major surgeries		
GABG	19617 (4)	167 (0.04)
Lobectomy	37348 (8)	36642 (10)
Orthopedic surgery	212501 (45)	138757 (37)
Surgery for diseases of liver, gall bladder, and pancreas	64788 (14)	63543 (17)
Gastrointestinal resection and esophagectomy	93624 (20)	95305 (25)
Urological surgery	45449 (10)	42169 (11)
Antihypertensive class		
One class	225731 (48)	NA
Two classes	172141 (36)	NA
Three classes	58456 (12)	NA
≥Four classes	16999 (4)	NA
Thiazide and thiazide-like	24625 (5)	NA

diuretics		
CCBs	359461 (76)	NA
RASIs	258134 (55)	NA
MRA	45190 (10)	NA
Beta blockers	105011 (22)	NA
Alpha blockers	22981 (5)	NA
Loop diuretics	91085 (19)	21782 (6)
Year		
2018	247059 (52)	197997 (53)
2019	226268 (48)	178586 (47)

563 Data are presented as number (percentage) or median (interquartile range).

564 BMI, body mass index; CABG, coronary artery bypass grafting; CCB, calcium channel

565 blocker; MRA, mineral corticoid receptor antagonist; RASi,

566 renin–angiotensin–aldosterone system inhibitor; NA, not applicable.

567

568 **Table 2. Number of antihypertensive classes and risk for mortality or functional**

569 **decline after survival in patients undergoing major surgeries.**

	n/N	Model 1	Model 2	Model 3	Model 4
No antihypertensive drugs	25207/376583	Reference	Reference	Reference	Reference
One class	22063/225731	1.20 (1.18–1.23)	1.20 (1.17–1.22)	1.17 (1.14–1.19)	1.12 (1.10–1.14)
Two classes	17558/172141	1.23 (1.20–1.25)	1.20 (1.18–1.23)	1.14 (1.12–1.17)	1.14 (1.04–1.09)
Three classes	6861/58456	1.42 (1.38–1.47)	1.42 (1.38–1.46)	1.30 (1.26–1.34)	1.11 (1.08–1.15)
≥Four classes	2225/16999	1.57 (1.49–1.65)	1.58 (1.50–1.67)	1.43 (1.36–1.51)	1.12 (1.07–1.19)

570 Model 1: Adjusted for age, sex, and type of major surgeries (CABG, thoracic lobectomy,

571 orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and

572 urological surgery)

573 Model 2: Model 1 plus BMI and Barthel Index score on admission.

574 Model 3: Model 2 plus DM, CVD, CKD, emergency admission, and admission year.

575 Model 4: Model 3 plus loop diuretics.

576 CABG, coronary artery bypass grafting; BMI, body mass index; DM, diabetes mellitus;

577 CVD, cardiovascular disease; CKD, chronic kidney disease; CI, confidence interval;

578 OR, odds ratio.

579

Table 3. Combinations of antihypertensive classes and perioperative outcomes following major surgeries in Japanese adults.

	Composite outcome		Death		Functional decline	
	OR (95%CI)	P value	OR (95%CI)	P value	OR (95%CI)	P value
<u>One class</u>						
TH	Reference		Reference		Reference	
CCB	0.89 (0.73–1.08)	0.2	0.91 (0.55–1.53)	0.7	0.88 (0.72–1.08)	0.2
RASi	0.77 (0.63–0.93)	0.008	0.58 (0.34–0.99)	0.044	0.79 (0.64–0.97)	0.022
MRA	1.11 (0.91–1.36)	0.3	1.49 (0.88–2.51)	0.1	0.95 (0.76–1.18)	0.6
β-blockers	1.14 (0.92–1.42)	0.2	0.59 (0.31–1.12)	0.1	1.27 (1.01–1.60)	0.040
α-blockers	1.10 (0.90–1.34)	0.4	1.60 (0.95–2.69)	0.1	0.99 (0.80–1.22)	0.9
<u>Two classes</u>						
TH/CCB	Reference		Reference		Reference	
TH/RASi	0.68 (0.60–0.77)	<0.001	0.20 (0.09–0.41)	<0.001	0.76 (0.67–0.86)	<0.001
CCB/RASi	0.78 (0.75–0.82)	<0.001	0.47 (0.41–0.52)	<0.001	0.85 (0.81–0.89)	<0.001
RASi/other	0.80 (0.75–0.86)	<0.001	0.75 (0.65–0.87)	<0.001	0.84 (0.78–0.90)	<0.001
Other/other	1.13 (1.03–1.23)	0.010	1.15 (0.99–1.34)	0.07	1.01 (0.90–1.12)	0.9
<u>Three classes</u>						
TH/CCB/other	Reference		Reference		Reference	
TH/CCB/RASi	0.72 (0.49–0.82)	<0.001	0.43 (0.31–0.60)	<0.001	0.79 (0.70–0.89)	<0.001
TH/RASi/other	0.87 (0.49–1.12)	0.2	0.62 (0.36–1.07)	0.09	0.98 (0.79–1.22)	0.9
CCB/RASi/other	0.82 (0.52–0.86)	<0.001	0.75 (0.63–0.89)	0.001	0.88 (0.80–0.97)	0.011
RASi/others	0.78 (0.50–1.65)	<0.001	0.55 (0.43–0.70)	<0.001	0.91 (0.79–1.05)	0.2
Others	1.66 (1.02–2.69)	0.040	0.72 (0.28–1.81)	0.5	2.19 (1.29–3.72)	0.004
<u>≥Four classes</u>						
TH/CCB/others	Reference		Reference		Reference	
TH/CCB/RASi/ot	0.63 (0.49–0.82)	0.001	0.55 (0.36–0.86)	0.008	0.75 (0.55–1.03)	0.07
TH/RASi/others	0.74 (0.49–1.12)	0.2	0.58 (0.27–1.23)	0.2	0.90 (0.56–1.45)	0.7
CCB/RASi/others	0.67 (0.52–0.86)	0.002	0.50 (0.34–0.76)	0.001	0.83 (0.62–1.13)	0.2
RASi/others	0.91 (0.50–1.65)	0.8	0.55 (0.18–1.65)	0.3	1.25 (0.64–2.46)	0.5

582 Multivariate logistic regression models adjusted for age, sex, type of major surgeries
 583 (CABG, thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery,
 584 gastrointestinal resection, and urological surgery), BMI, Barthel Index score on
 585 admission, DM, CVD, CKD, emergency admission, admission year, and loop diuretics.
 586 CABG, coronary artery bypass grafting; BMI, body mass index; DM, diabetes mellitus;
 587 CVD, cardiovascular disease; CKD, chronic kidney disease; CI, confidence interval;
 588 OR, odds ratio; CCB, calcium channel blocker; MRA, mineral corticoid receptor
 589 antagonist; RASi, renin–angiotensin–aldosterone system inhibitor; TH,
 590 thiazide/thiazide-like diuretics.
 591

592 **Figure legends**

593 **Figure 1. Antihypertensive classes and prevalence of postoperative death or** 594 **functional decline after survival among patients undergoing major surgeries. a, b.**

595 prevalence of all-cause in-hospital deaths (a) and functional decline (b) among nonusers
596 and users of one, two, three, or four or more antihypertensive classes according to age
597 category. Functional decline was defined as a ≥ 5 -point decrease in the Barthel Index
598 score between admission and discharge. Each spot represents a mean, whereas the solid
599 lines represent the corresponding 95% CI. CI, confidence interval; n/N, number of
600 events/number of participants.

601 **Figure 2. Association between surgery type and effects of antihypertensive classes**
602 **on postoperative outcomes among patients with hypertension.** Multivariable logistic
603 regression models adjusted for age, sex, number of antihypertensive classes, BMI,
604 Barthel Index score on admission, DM, CVD, CKD, emergency admission, year, and
605 loop diuretics according to surgery type. The type of major surgeries included CABG,
606 thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal
607 resection, and urological surgery. CABG, coronary artery bypass grafting; BMI, body
608 mass index; DM, diabetes mellitus; CVD, cardiovascular disease; CKD, chronic kidney
609 disease; CI, confidence interval; OR, odds ratio; CCB, calcium channel blocker; MRA,


610 mineral corticoid receptor antagonist; RASi, renin–angiotensin–aldosterone system

611 inhibitor.

612

a

Overall in-hospital death



b

Survival with functional decline

